Salivary defensins and their importance in oral health and disease

Current Pharmaceutical Design

Volumn 13, Issue 30, 2007, Pages 3065-3072

  Abiko, Yoshihiro ^a   Saitoh, Masato ^a  

^a HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

Antimicrobial peptide; Clinical application; Defensin; Disease; Gingival fluid; Oral; Saliva; Salivary gland

Indexed keywords

ALPHA DEFENSIN; BETA DEFENSIN; BETA DEFENSIN 2; BETA DEFENSIN 3; DEFENSIN; LENTIVIRUS VECTOR; MESSENGER RNA; POLYPEPTIDE ANTIBIOTIC AGENT;

ANTIMICROBIAL ACTIVITY; BLOOD CELL; DEFENSE MECHANISM; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; EPITHELIUM CELL; GENE THERAPY; HUMAN; INNATE IMMUNITY; MOUTH DISEASE; MOUTH MUCOSA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SALIVA; SALIVARY GLAND;

ANIMALS; DEFENSINS; GENE EXPRESSION REGULATION; HUMANS; MOUTH DISEASES; MOUTH MUCOSA; ORAL HEALTH; SALIVA; SALIVARY GLANDS;

EID: 34548690015     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207782110417     Document Type: Review

References (122)

1. Pomahac B, Svensjo T, Tao F, Brown H, Eriksson E. Tissue engineering of skin. Crit Rev Oral Biol Med 1998; 9: 333-44.
2. Presland RB, Dale BA. Epithelial structural protein of the skin and oral cavity: Function in health and disease. Crit Rev Oral Biol Med 2000; 11: 383-408.
3. Mandel ID. The functions of saliva. J Dent Res 1987; 66: 623-7.
4. Amerongen AV, Veerman EC. Saliva-the defender of the oral cavity. Oral Dis 2002; 8: 12-22.
5. De Smet K, Contreras R. Human antimicrobial peptides: Defensins, cathelicidins and histatins. Biotechnol Lett 2005; 27: 1337-47.
6. Valimaa H, Waris M, Hukkanen V, Blankenvoorde MF, Nieuw Amerongen AV, Tenovuo J. Salivary defense factors in herpes simplex virus infection. J Dent Res 2002; 81: 416-21.
7. Murakami M. Ohtake T, Dorchner RA, Gallo RL. Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. Dent Res 2002; 81: 845-50.
8. Bensch KW, Raida M, Hans-Jurgen M, Schulz-Knappe P, Forssmann W-G. hBD-1: A novel β-defensin from human plasma. FEBS Lett 1995; 368: 331-5.
9. Harder J, Siebert R, Zhang Y, Matthiesen P, Christophers E, Schlegelberger B, et al. Mapping of the gene encoding human, β-defensin 2 (DEFB2) to chromosome region 8p22-p23.1. Genomics 1997; 46: 472-75.
10. Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of human beta-defensin-3, a novel human inductible peptide antibiotics. J Biol Chem 2001; 276: 5707-13.
11. Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF. Natural peptide antibiotics of human neutrophils. J Clin Invest 1985; 76: 1424-35.
12. Schutte BC, Mitros JP, Bartlett JA, Walters JD, Jia HP, Welsh MJ, et al. Discovery of five conserved β-defensin gene clusters using a computational search strategy. Proc Natl Acad Sci USA 2002; 99: 2129-33.
13. Braff MH, Gallo RL. Antimicrobial peptides: An essential component of the skin defensive barrier. Curr Top. Microbiol Immunol. 2006; 306: 91-110.
14. Klotman ME, Chang TL. Defensins in innate antiviral immunity. Nat Rev Immunol 2006; 6: 447-56.
15. Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J. Human beta-defensins. Cell Mol Life Sci 2006; 63: 1294-313.
16. Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol 2005; 6: 551-7.
17. Risso A. Leukocyte antimicrobial peptides: Multifunctional effector molecules of innate immunity. J Leukocyte Biol 2000; 68: 785-92.
18. Ganz T, Lehrer RI. Defensins. Curr Opin Immunol 1994; 6: 584-9.
19. Ouellette AJ, Selested ME. Paneth cell defensins: Endogeneous peptide components of intestinal host defense. FASEB J 1996; 10: 1280-9.
20. Hecht G. Innate mechanism of epithelial host defense: Spotlight on intestine. Am J Physiol 1999; 277: 351-8.
21. Goebel C, Mackay LG, Vickers ER, Mather LE. Determination of defensin HNP-1, HNP-2, and HNP-3 in human saliva by using LC/MS. Peptides 20000; 21: 757-65.
22. Tanida T, Okamoto T, Okamoto A, Wang H, Hamada T, Ueta E, et al. Decreased excretion of antimicrobial proteins and peptides in saliva of patients with oral candidiasis. J Oral Pathol Med 2003; 32: 586-94.
23. Dale BA, Tao R, Kimball JR, Jurevic RJ. Oral antimicrobial peptides and biological control of caries. BMC Oral Health 2006; 6: 1-7.
24. Mizukawa N, Sugiyama K, Fukunaga J, Ueno T, Mishima K, Takagi S, et al. Defensin-1, a peptide detected in the saliva of oral squamous cell carcinoma patients, Anticancer Res 1998; 18: 4645-9.
25. Mizukawa N, Sugiyama K, Ueno T, Mishima K, Takagi S, Sugahara T. Level of human defensin-1, an antimicrobial peptide in saliva of patients with oral inflammation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 87: 539-43.
26. Mizukawa N, Sugiyama K, Ueno T, Mishima K, Takagi S, Sugahara T. Defensin-1, an antimicrobial peptide present in the saliva of patients with oral disease. Oral Dis 1999; 5: 139-42.
27. Pisano E, Cabras T, Montaldo C, Piras V, Inzitari R, Ohni C, et al. Peptides of human gingival crevicular fluid determined by HPLC-ESI-MS. Eur J Oral Sci 2005; 113: 462-8.
28. Diamond DL, Kimball,JR, Krisanaprakornkit S, Ganz T, Dale BA. Detection of beta-defensins secreted by human oral epithelial cells. J Immunol Methods 2001; 256: 68-76.
29. Lundy FT, Orr DF, Shaw C, Lamey PJ, Linden GJ. Detection of individual human neutrophil alpha-defensins (human neutrophil peptides 1, 2 and 3) in unfractionated gingival crevicular fluid-a MALDI-MS approach. Mol Immunol 2005; 42: 575-9.
30. Mckay MS, Olson E, Hesla MA, Panyutich A, Ganz T, Perkins S, et al. Immunomagnetic recovery of human neurophil defensins from the human gingival crevice. Oral Microbiol Immun 1999; 14: 190-3.
31. Weinberg A, Krisanaprakornkit S, Dale BA: Epithelial anitimicrobial peptides: Review and significant for oral applications. Crit Rev Oral Biol Med 1998; 9: 399-414.
32. Schroder JM, Harder J. Human beta-defensin-2. In J Biochem Cell Biol 1999; 31: 645-51.
33. Dale BA, Krishnaprakornkit S. Defensin antimicrobial peptides in the oral cavity. J Oral Pathol Med 2001; 30: 321-7.
34. Garcia J-RC, Jaumann F, Schulz S, Krause A, Rodriguez-JF, Forssmann U, et al. Identification of a novel multifunctional β-defensin (human β-defensin 3) with specific antimicrobial activity. Cell Tissue Res 2001; 306: 257-64.
35. Harder J, Mayer-Hoffert U. Teran LM, Schwichtenberg L, Bartels J, Maune S, et al. Mucoid pseudomonas aeruginosa, TNF-α, and IL-1β, but not IL-6 induces human β-defensin-2 in respiratory epithelia. Am J Respir Cell Mol Biol 2000; 22: 714-21.
36. Bals R, Wang X, Meegalla. RL, Wattler S, Weiner DJ Nehls MC, Wilson JM. Mouse β-defensin 3 is an inducible antimicrobial peptide expressed in the epithelia of multiple organs. Infect Immun 1999; 67: 3524-47.
37. Becker MN, Diamond G, Verghese MW, Randell SH. CD14-dependent lipopolysaccharide-induced β-defensin-2 expression in human tracheobronchial epithelium. J Biol Chem 2000; 275: 29731-6.
38. Valore EV, Park CH, Quayle AJ, Wiles KR, McCray Jr BB, Ganz T. Human beta-defensin-1: An antimicrobial peptide of urogenital tissues. J Clin Invest 1998; 101: 1633-42.
39. Bals R, Goldman MJ, Wilson JM. Mouse β-defensin 1 is a salt-sensitive antimicrobial peptide present in epithelia of the lung and urogenital tract. Infect Immun 1998; 66: 1225-32.
40. Garcia J-RC, Krause A, Schulz S, Rodriguez-J F, Kluver E, Adermann K, et al. Human β-defensin 4: A novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J 2001; 15: 1819-21.
41. Jia HP, Schutte BC, Schudy A, Linzmeier R, Guthmiller JM, Johnson GK, Tack BF, et al. Discovery of new human beta-defensins using a genomic-based approach. Gene 2001; 263: 211-8.
42. Dunsche A, Acil Y, Dommisch H, Siebert R, Schroder JM, Jepsen S. The novel human beta-defensin-3 is widely expressed in oral tissues. Eur J Oral Sci 2002; 110: 121-4.
43. Mathews M, Jia HP, Guthmiller JM, Losh G, Graham S, Johnson GK, et al. Production β-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun 1999; 67: 2740-5.
44. Tao R, Jurevic RJ, Coulton KK, Tsutsui MT, Roberts MC, Kimball JR, et al. Salivary antimicrobial peptide expression and dental caries experience in children. Antimicrob Agents Ch 2005; 49: 3883-8.
45. Dale BA, Kimball JR, Krisanaprakornkit S, Roberts F, Robinovitch M, O'Neal R, et al. Localized antimicrobial peptide expression in human gingival. J Periodont Res 2001; 35: 1-10.
46. Abiko Y, Nishimura M, Kusano K, Yamazaki M, Arakawa T, Takuma T, et al. Upregulated expression of human β defensin-1 and -3 mRNA during differestiation of keratinocyte immortalized cell lines, HaCaT and PHK16-0b. J Dermatol Sci 2003; 31: 225-8.
47. Dale BA. Periodontal epithelium: A newly recognized role in health and disease. Periodontol 2000 2002; 30: 70-8.
48. Harder J, Mayer-Hoffert U, Wehkamp K, SchwichtenbergL, AchroderJM. Differential gene induction of human beta-defensins (hBD-1, -2, -3, and -4) in keratinocytes is inhibited by retinoic acid. J Invest Dermatol 2004; 123: 522-9.
49. Abiko Y, Suraweera AK, Nishimura M, Arakawa T, Takuma T, Mizoguchi I, et al. Differential expression of human beta-defensin 2 in keratinized and non-keratinized oral epithelial lesions; immunohistochemistry and in situ hybridization. Virchow Arch 2001; 438: 248-53.
50. Zao C, Wang I, Lehrer RI. Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett 1996; 396: 319-22.
51. Bonass WA, High AS, Owen PJ, Devine DA. Expression of beta-defensin genes by human salivary glands. Oral Microbiol Immun 1999; 14: 371-72.
52. Dunsche A, Acil Y, Siebert R, Harder J, Schroder JM, Jepsen S. Expression profile of human defensins and antimicrobial proteins in oral tissues. J Oral Pathol Med 2001; 30: 154-8.
53. Saitoh M, Abiko Y, Shimabukuro S, Kusano K, Nishimura M, Arakawa T, et al. Correlated expression of human beta defensin-1, -2 and -3 mRNAs in gingival tissues of young children. Arch Oral Biol 2004; 49: 799-803.
54. Sahasrabudhe KS, Kimball JR, Morton TH, Weinberg A, Dale BA. Expression of the antimicrobial peptide, human beta-defensin 1, in duct cells of minor salivary glands and detection in saliva. J Dent Res 2000; 79: 1669-74.
55. Abiko Y, Nishimura M, Kusano K, Kaku T. Presence of human β-defensin 2 peptide in keratinization in salivary gland tumor. Oral Med Pathol 2000; 5: 95-7.
56. Abiko Y, Jinbu Y, Noguchi T, Nishimura M, Kusano K, Amaratunga P, et al. Upregulation of human beta-defensin 2 peptide expression in oral lichen planus, leukoplakia and candidiasis; an immunohistochemical study. Pathol Res Pract 2002; 198: 537-42.
57. Shimono M, Ishikawa T, Enokiya Y, Muramatsu T, Matsuzaka K, Inoue T, et al. Biological characteristics of the junctional epithelium. J Electron Microsc 2003; 52: 627-39.
58. Duits LA, Revensbergen B, Rademaker M, Hiemstra PS, Nibbering PH. Expression of beta-defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells. Immunology 2002; 106: 517-25.
59. Tenovuo J. Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and lactoferrin in xerostomia: Efficacy and safety. Oral Dis 2002; 8: 23-9.
60. Ouhara K, Komatsuzawa H, Yamada S, Shiba H, Fujiwara T, Ohara M, et al. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, {beta}-defensins and LL37, produced by human epithelial cells. Antimicrob Agents Chemother 2005; 55: 888-96.
61. Vankeerberghen A, Nuytten H, Dierickx K, Quirynen M, Cassiman JJ, Cuppens H. Differential induction of human beta-defensin expression by periodontal commensals and pathogens in periodontal pocket epithelial cells. J Periodontol 2005; 76: 1293-303.
62. Nagaoka I, Hirota S, Yomogida S, Ohwada A, Hirata M. Synergistic actions of antibacterial neutrophil defensins and cathelicidins. Inflamm Res 2000; 49: 73-9.
63. Izutsu K, Johnson D, Schubert M, Wang E, Ramsey B, Tamarin A, et al. Electron microprobe analysis of human labial gland secretory granules in cystic fibrosis. J Clin Invest 1985; 75: 1951-6.
64. Ferguson DB. The flow rate and composition of human labial gland saliva, Arch Oral Biol 1999; 44(Suppl 1): S11-4.
65. Laube DM, Yim S, Ryan LK, Kisich KO, Diamond G. Antimicrobial peptides in the airway. Curr Top Microbiol 2006; 306: 153-82.
66. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997; 88: 553-60.
67. Mineshiba F, Takashiba S, Mineshiba J, Matsuura K, Kokeguchi S, Murayama Y. Antibacterial activity of synthetic human B defensin-2 against periodontal bacteria. J Int Acad Periodontol 2003; 5: 3540.
68. Maisetta G, Batoni G, Esin S, Raco, G, Bottai D, Favilli F, et al. Susceptibility of Streptococcus mutans and Actinobacillus actino-mycetemcomitans to bactericidal activity of human beta-defensin 3 in biological fluids. Antimicrob Agents Chemother 2005; 49: 1245-8.
69. Sahasrabudhe KS, Kimball JR, Morton TH, Weinberg A, Dale BA. Expression of the antimicrobial peptide, human beta-defenlin 1, in duct cells of minor salivary gland and detection in saliva. J Dent Res 2000; 79: 1669-74.
70. Iontcheva I, Oppenheim FG, Troxler RF. Human salivary mucin MG1 selectively forms heterotypic complexes with amylase, proline-rich proteins, statherin, and histatins. J Dent Res 1997; 76: 734-43.
71. Biesbrock AR, Reddy MS, Levine MJ. Interaction of a salivary mucin-secretory immunoglobulin A complex with mucosal pathogens. Infect Immun 1991; 59: 3492-7.
72. Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, Lopez-Boado YS, Stratman JL, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999; 286: 113-7.
73. Uitto VJ, Salonen JI, Firth JD, Jousimies-Somer H, Saarialho-Kere U. Matrilysin (matrix metalloproteinase- 7) expression in human junctional epithelium. J Dent Res 2002; 81: 241-6.
74. Muramatsu T, Ohta K, Asaka M, Kizaki H, Shimono M. Expression and distribution of osteopontin and matrix metalloproteinase (MMP)-3 and -7 in mouse salivary glands. Eur J Morphol 2002; 40: 209-12.
75. Chen X, Niyonsaba F, Ushio H, Okuda D. Nagaoka I, Ikeda S, et al. Synergistic effect of antibacterial agents human beta-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli. J Dermatol Sci 2005; 40: 123-32.
76. Ali A, Niissalo S, Hietanen J, Laine M, Rautemaa R, Konttinen Y. Expression of alpha-defensin-1 in chronic hyperplastic candidosis. J Oral Pathol Med 2005; 34: 347-51.
77. Diamond G, Kaiser V, Rhodes J, Russell JP, Revins CL. Transcriptional regulation of β-defensin gene expression in tracheal epithelial cells. Infect Immun 2000; 68: 113-9.
78. Schroder JM, Harder J. Human beta-defensin-2. Int J Biochem Cell Biol 1999; 31: 645-51.
79. Krisanaprakomkit S, Kimball JR, Dale BA. Regulation of human beta-defensin-2 in gingival cells: The involvement of mitogen-activated protein kinase pathways but not the NF-kappa B transcription factor family. J Immunol, 2002; 168: 316-24.
80. Liu AY, Destoumieux D, Wong AV, Park CH, Valore EV, Liu L, et al. Human beta-defensin-2 production in keratinocyte is regulated by interleukin-1, bacteria and the state of differentiation. J Invest Dermatol 2002; 118: 275-81.
81. Moon SK, Lee HY, Li JD, Nagura M, Kang SH, Chun YM, et al. Activation of a Src-dependent Raf-MEK1/2-ERK signaling pathway is required for IL-1 alpha-induced upregulation of beta-defensin 2 in human middle ear epithelial cells. BBA-Mol Cell Res 2002; 1590: 41-51.
82. Schibli DJ, Hunter HN, Aseyev V, Starner TD, Wiencek JM, McCray PB, et al. The solution of structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus. J Biol Chem 2002; 277: 8279-89.
83. Tsutsumi-Ishii Y, Nagaoka I. NF-kappa B-mediated transcriptional regulation of human beta-defensin-2 gene following lipopolysac-charide stimulation. J Leukocyte Biol 2002; 71: 154-62.
84. Maisetta G, Batoni G, Esin S, Raco G, Bottai D, Favilli F, et al. Susceptibility of Streptococcus mutans and Actinobacillus actino-mycetemcomitans to bactericidal activity of human beta-defensin 3 in biological fluids. Antimicrob Agents Chemother 2005; 49: 1245-8.
85. Feucht EC, DeSanti CL, Weinberg A. Selective induction of human beta-defensin mRNAs by Actinobacillus actinomycetemcomitans in primary and immortalized oral epithelial cells. Oral Microbiol Immun 2003; 18: 359-63.
86. Abiko Y, Mitamura J, Nishimura M, Muramatsu T, Inoue T, Shimono M, et al. Pattern of expression of beta-defensins in oral squamous cell carcinoma. Cancer Lett 1999; 143: 37-43.
87. Brogden KA, Heidari M, Sacco RE, Palmquist D, Guthmiller JM, Johnson GK, et al. Defensin-induced adaptive immunity in mice and its potential in preventing periodontal disease. Oral Microbiol Immun 2003; 18: 95-9.
88. Darnell M, Aras HC, Magnusson B, Ekstrom J. Lipopolysaccharide induced-in vivo increases in beta-defensins of the rat parotid gland. Arch Oral Biol 2006; 51: 769-74.
89. Fang XM, Shu Q, Chen QX, Book M, Sahl HG, Hoeft A, et al. Differential expression of alpha- and beta-defensins in human peripheral blood. Eur J Clin Invest 2003; 33: 82-7.
90. Nederfors T. Xerostomia and hyposalivation. Adv Dent Res 2000; 14: 48-56.
91. Shigeyama Y, Anzai T, Ishizaka A, Yoshida A, Kurino H, Takehara N. Evaluation of Chromogranin A in dry mouse patients. J Dent. Hlth 2006; 56: 596.
92. Butcher SK, Lord JM. Stress responses and innate immunity: Aging as a contributory factor. Aging Cell 2004; 3: 151-60.
93. Krisanaprakornkit S, Kimball JR, Weinberg A, Darveau RP, Bainbridge BW, Dale BA. Inducible expression of human beta-defensin 2 by Fusobacterium nucleatum in oral Epithelial cells: Multiple signaling pathway and role of commensal bacteria in innate Immunity and the epithelial barrier. Infect Immun 2000; 68: 2907-15.
94. Dommisch H, Acil Y, Dunsche A, Winter J, Jepsen S. Differential gene expression of human beta-defensins (hBD-1, -2, -3) in inflammatory gingival diseases. Oral Microbiol Immun 2005; 20: 186-90.
95. Bissell J, Joly S, Johnson GK, Organ CC, Dawson D, McCray PB Jr, et al. Expression of beta-defensins in gingival health and in periodontal disease. J Oral Pathol Med 2004; 33: 278-85.
96. Jurevic RJ, Bai M, Chadwick RB, White TC, Dale BA. Single-nucleotide polymorphisms (SNPs) in human beta-defensin 1: High-throughput SNP assays and association with Candida carriage in type I diabetics and nondiabetic controls. J Clin Microbiol 2003; 41: 90-6.
97. Boniotto M, Hazbon MH, Jordan WJ, Lennon GP, Eskdale J, Alland D, et al. Novel hairpin-shaped primer assay to study the association of the -44 single-nucleotide polymorphism of the DEFB1 gene with early-onset periodontal disease. Clin Diagn Lab Immun 2004; 11: 766-9.
98. Wohlfahrt JC, Wu T, Hodges JS, Hinrichs JE, Michalowicz BS. No association between selected candidate gene polymorphisms and severe chronic periodontitis. J Periodontol 2006; 77: 426-36.
99. Shiomi K, Nakazato M, Ihi T, Kanagawa K, Matsuo H, Matsukura S. Establishment of radioimmunoassay for human neutrophil peptides and their increases in plasma and neutrophil in infection. Biochem Biophys Res Common 1993; 195: 1336-44.
100. Dorland WAN. Editor. Dorland's illustrated medical dictionary, 28th ed. Philadelphia, W.B. Saunders co. 1994;
101. Loesche WJ. The antimicrobial treatment of periodontal disease: Changing the treatment paradigm. Crit Rev Oral Biol Med 1999; 10: 245-75.
102. Slots J, Jorgensen MG. Efficient antimicrobial treatment in periodontal maintenance care. J Am Dent Assoc 2000; 131: 1293-304
103. Miyasaki KT, Lehrer RI. Beta-sheet antibiotic peptides as potential dental therapeutics. Int J Antimicrob Agents 1998; 9: 269-80
104. Killoy WJ. Chemical treatment of periodontitis: Local delivery of antimicrobials. Int Dent J 1998; 48(Suppl 1): 305-15.
105. Ciancio SG. Site specific delivary of antimicrobial agents for periodontal disease. Gen Dent 1999; 47: 172-8.
106. Schwach-Abdellaoui K, Vivien-Castioni N, Gurry R. Local delivery of antimicrobial agents for the treatment of periodontal diseases. Eur J Pharm Biopharm 2000; 50: 83-99.
107. Sawamura D, Goto M, Shibaki A, Akiyama M, McMillan JR, Abiko Y, et al. Beta defensin-3 engineered epidermis shows highly protective effect for bacterial infection. Gene Ther 2005; 12: 857-61.
108. Cotrim AP, Mineshiba F, Sugito T, Samuni Y, Baum BJ. Salivary gland gene therapy. Dent Clin North Am 2006; 50: 157-73.
109. Baum BJ. Prospect for re-engineering salivary glands. Adv Dent Res 2000; 14: 84-8.
110. Baum BJ, Kok M, Tran SD, Yamano S. The impact of gene therapy on dentistry: A revisiting after therapies. J Am Dent Assoc 2002; 133: 35-44.
111. Yin C, Dang HN, Gazor F, Huang GT. Mouse salivary glands and human beta-defensin-2 as a study model for antimicrobial gene therapy: technical considerations. Int J Antimicrob Agents 2006; 28: 352-60.
112. Yin C, Dang HN, Zhang HB, Gazor F, Kim D, Sorensen OE, Huang GT. Capacity of human beta-defensin expression in gene-transduced and cytokine-induced cells. Biochem Biophys Res Commun 2006; 339: 344-54.
113. Lichtenstein A, Ganz T, Selested ME, Lehrer RI. In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood 1996; 69: 1407-10.
114. Lichtenstein A, Ganz T, Nguyen TM, Selsted ME, Lehrer RI. Mechanism of target cytolysis by peptide defensins: Target cell; metabolic activity, possibly endocytosis, are crucial for expression of cytotoxity. J Immunol 1988; 140: 2686-94.
115. Lichtenstein A. Mechanism of mammalian cell lysis mediated by peptide defensisn. Evidence for an initial alteration of the plasma membrane. J Clin Invest 1991; 88: 93-100.
116. Muller CA, Markovic-Lipkovski J, Klatt T, Gamper J, Schwarz G, Beck H, et al. Human α-defensins HNPs-1, -2 and -3 in renal cell carcinoma. Am J Pathol 2002; 160: 1311-24.
117. Nishimura M, Abiko Y, Kurashige Y, Takeshima M, Yamazaki M, Kusano K, et al. Effect of defensin peptides on eukaryotic cells: Primary epithelial cells, fibroblasts and squamous cell carcinoma cell lines. J Dermatol Sci 2004; 36: 87-95.
118. Yang D, Chetrov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, et al. β-Defensin: Linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999; 286: 525-8.
119. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002; 298: 1025-9.
120. Garzino-Demo A. Chemokines and defensins as HIV suppressive factors: An evolving story. Curr Pharm Des 2007; 13(2): 163-72.
121. Salvi GE, Lang NP. The effects of non-steroidal anti-inflammatory drugs (selective and non-selective) on the treatment of periodontal diseases. Curr Pharm Des 2005; 11(14): 1757-69.
122. Yalcin AS. Emerging therapeutic potential of whey proteins and peptides. Curr Pharm Des 2006; 12(13): 1637-43.